{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:18:18Z","timestamp":1793607498946,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40257-025-01003-0","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:47:40Z","timestamp":1768366060000},"page":"391-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b\/4 Study (LEVEL UP)"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Calimlim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Armendariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/s0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(21)00588-2.","journal-title":"Lancet"},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158:404\u201313. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0029.","journal-title":"JAMA Dermatol"},{"key":"1003_CR3","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/nejmoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348. https:\/\/doi.org\/10.1056\/nejmoa1610020.","journal-title":"N Engl J Med"},{"issue":"9","key":"1003_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"key":"1003_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2023.05.033","volume":"89","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023;89:478\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.033.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1003_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2024;192(1):36\u201345. https:\/\/doi.org\/10.1093\/bjd\/ljae404.","journal-title":"Br J Dermatol"},{"key":"1003_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm-Venereol. 1980;60:44\u20137. https:\/\/doi.org\/10.2340\/00015555924447.","journal-title":"Acta Derm-Venereol"},{"key":"1003_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/s0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(21)00589-4.","journal-title":"Lancet"},{"key":"1003_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","volume":"149","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results. J Allergy Clin Immunol. 2022;149:977-987 e14. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.036.","journal-title":"J Allergy Clin Immunol"},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87:784\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.012.","journal-title":"J Am Acad Dermatol"},{"key":"1003_CR11","doi-asserted-by":"crossref","unstructured":"Eyerich K, Torres T, Lynde CW, et al. Higher levels of skin clearance across body regions with upadacitinib versus dupilumab in patients with moderate-to-severe atopic dermatitis. https:\/\/eposters.aad.org\/abstracts\/60920. Presented at: Accessed 7 Apr 2025.","DOI":"10.1016\/j.jaad.2025.05.865"},{"issue":"Supplement_2","key":"1003_CR12","doi-asserted-by":"publisher","first-page":"ii35","DOI":"10.1093\/bjd\/ljad498.037","volume":"190","author":"C Bunick","year":"2024","unstructured":"Bunick C, Chovatiya R, Guttman E, et al. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. Br J Dermatol. 2024;190(Supplement_2):ii35\u20136. https:\/\/doi.org\/10.1093\/bjd\/ljad498.037.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1003_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542275","volume":"241","author":"JP Thyssen","year":"2024","unstructured":"Thyssen JP, Rosmarin D, Costanzo A, et al. Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: analysis from the Heads Up study. Dermatology. 2024;241(1):1\u20139. https:\/\/doi.org\/10.1159\/000542275.","journal-title":"Dermatology"},{"issue":"1","key":"1003_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40261-023-01336-w","volume":"44","author":"M Napolitano","year":"2024","unstructured":"Napolitano M, Ferrucci SM, Foggia L, et al. Comparison of long-term effectiveness and safety of upadacitinib for atopic dermatitis between dupilumab-exposed and dupilumab-na\u00efve patients. Clin Drug Investig. 2024;44(1):71\u20137. https:\/\/doi.org\/10.1007\/s40261-023-01336-w.","journal-title":"Clin Drug Investig"},{"key":"1003_CR15","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5243","volume":"103","author":"CM Boesjes","year":"2023","unstructured":"Boesjes CM, Gang LFVD, Zuithoff NPA, et al. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and\/or baricitinib: results from the BioDay Registry. Acta Dermato-Venereol. 2023;103:5243. https:\/\/doi.org\/10.2340\/actadv.v103.5243.","journal-title":"Acta Dermato-Venereol"},{"issue":"7","key":"1003_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15575","volume":"35","author":"K Hayama","year":"2022","unstructured":"Hayama K, Fujita H. Improvement of dupilumab\u2010associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis. Dermatol Ther. 2022;35(7):e15575. https:\/\/doi.org\/10.1111\/dth.15575.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1003_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.320","volume":"91","author":"B Nicolas-Ruanes","year":"2024","unstructured":"Nicolas-Ruanes B, Berna-Rico E, Garcia-Mouronte E, et al. 52132 real-world experience of switching atopic dermatitis treatment to upadacitinib after primary or secondary dupilumab failure. J Am Acad Dermatol. 2024;91(3):AB78. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.320.","journal-title":"J Am Acad Dermatol"},{"issue":"Supplement_2","key":"1003_CR18","doi-asserted-by":"publisher","first-page":"ii60","DOI":"10.1093\/bjd\/ljad498.063","volume":"190","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Grada A, Knapp KD, Munoz B, Crawford JM, Silverberg JI. 568 - Persistent inadequate disease control and therapeutic inertia in moderate-to-severe atopic dermatitis: a 12-month longitudinal analysis of real-world outcomes from TARGET-DERM registry. Br J Dermatol. 2024;190(Supplement_2):ii60\u20131. https:\/\/doi.org\/10.1093\/bjd\/ljad498.063.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1003_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2428729","volume":"35","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Calimlim BM, Grada A, et al. Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry. J Dermatolog Treat. 2024;35(1):2428729. https:\/\/doi.org\/10.1080\/09546634.2024.2428729.","journal-title":"J Dermatolog Treat"},{"key":"1003_CR20","unstructured":"Greater skin clearance and itch improvement in atopic dermatitis are associated with the achievement of stringent patient-reported outcomes: integrated analysis of three upadacitinib Phase 3 trials. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10903934\/#sec64. Accessed 5 Feb 2025."},{"key":"1003_CR21","doi-asserted-by":"publisher","unstructured":"Polaskey MT, Fakhraie S, Daftary K, Chovatiya R. An open-label prospective observational study of tralokinumab in atopic dermatitis patients with inadequate response to dupilumab. Dermatitis\u00ae. Published online 2024. https:\/\/doi.org\/10.1089\/derm.2024.0084.","DOI":"10.1089\/derm.2024.0084"},{"issue":"1","key":"1003_CR22","doi-asserted-by":"publisher","DOI":"10.25251\/skin.9.supp.512","volume":"9","author":"J Silverberg","year":"2025","unstructured":"Silverberg J, Ackerman L, Bagel J, et al. Lebrikizumab improves atopic dermatitis and quality of life in patients with moderate-to-severe atopic dermatitis previously treated with dupilumab: results from the ADapt Trial. SKIN J Cutaneous Med. 2025;9(1):s512. https:\/\/doi.org\/10.25251\/skin.9.supp.512.","journal-title":"SKIN J Cutaneous Med"},{"key":"1003_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20229","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.20229.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-01003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-01003-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-01003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:19:42Z","timestamp":1774696782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-01003-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-01003-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.G. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber, and Palvella; a consultant for AbbVie, Almirall, Apogee, Arcutis, Connect BioPharma, Eli Lilly, EPI Health\/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, Takeda, and UCB; and a speaker for and received honoraria from Allergan, Almirall, LEO Pharma, and UCB. N. Magnolo has received honoraria for participation on advisory boards, as a speaker and\/or for consultancy from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma. A. Moore has received honoraria or research funds from Abbvie, Aclaris, Acrotech, Arcutis, Bayer, Bristol Myers Squibb, Cara, Eli Lilly, Galderma, Genentech Roche, Incyte, Janssen, Novartis, Pfizer, Rapt, Regeneron, Roche, and Sanofi. M. Abe has been an investigator, consultant and\/or speaker for AbbVie, Amgen, UCB, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, Bristol Myers Squibb, Kyowa-Kirin, Sun Pharma, Maruho and Torii. X. Gao has served as speaker for Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., and Sanofi, consultancy\/advisory board member for AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi \u2013 investigator; AbbVie, AstraZeneca, BMS, Eli Lilly, Huarun, JiaLan, LEO Pharma, Pfizer, Puqi and Sanofi. C. Lynde has acted as a principal investigator, speaker and\/or consultant for AbbVie, Amgen AnatpysBio, Avillon, Arcutis, Bristol-Myers Squibb, Celgene Cipher Genentech, GlenMark, Incyte, Janssen, Leo Pharma, Kyowa, Pfizer, and Merck. N. Ibrahim, G. Levy, B.M. Calimlim, X. Wu, Y. Armendariz, and A. Grada are full-time employees of AbbVie Inc and may hold AbbVie stock and\/or stock options. K. Eyerich has received grants and personal fees from AbbVie; has received personal fees from Almirall, Bristol Myers Squibb, LEO Pharma, Lilly, Janssen, Novartis, UCB, and Sanofi; and has received grants from Lilly, LEO Pharma, Janssen, Novartis, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest disclosures"}},{"value":"All authors were involved in the interpretation of the data, preparation, and critical review of the manuscript, and approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was performed in accordance with the Declaration of Helsinki 1964 and its later amendments. Independent ethics committees or institutional review boards approved the study protocol, informed consent form(s), and recruitment materials before patient enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The patients in this manuscript have given written informed consent to publication of their case details.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Patients provided written informed consent before screening.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AbbVie is committed to responsible data sharing regarding the trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for trial data for unlicensed products and indications. These trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the USA and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}